Denali Therapeutics Inc.
DNLI
Key stats
- Open
- 19.39
- Day high
- 19.60
- Day low
- 18.80
- Previous close
- 19.73
- Volume
- 1.31M
- VWAP
- 19.10
- 52-week high
- 27.30
- 52-week low
- 15.34
- Market cap
- 3.16B
- Shares out
- 160.29M
- Employees
- 507
- Listed
- 2017
About Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SOUTH SAN FRANCISCO, CA · denalitherapeutics.com
Options · expiring Nov 20
Nov 12, 3:58 PM ET- Call open interest
- 710
- Put open interest
- 384
- Put/call
- 0.54
- At-the-money IV
- 71.6%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 20 put | 0.80 | Nov 11, 12:15 PM | 209 | 208 | 44.1% |
| 17.50 call | 1.62 | Oct 19, 10:22 AM | 140 | 140 | 106.0% |
| 20 call | 1.73 | Nov 4, 10:07 AM | 100 | 163 | 71.6% |
| 15 call | 7.00 | Nov 4, 9:31 AM | 20 | 0 | — |
| 22.50 call | 0.10 | Nov 12, 11:56 AM | 20 | 407 | 126.7% |
| 22.50 put | 3.73 | Nov 3, 2:47 PM | 4 | 13 | 79.9% |
Quarterly results
Massive · Nov 3, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $17.78M | $3.60M | $0 | $0 |
| Gross profit | $17.59M | $3.51M | $0 | $0 |
| Operating income | −$126.75M | −$130.54M | −$137.36M | −$137.37M |
| Net income | $65.74M | −$127.55M | −$129.81M | −$128.55M |
| Diluted EPS | 0.37 | -0.68 | -0.69 | -0.73 |
| Operating cash flow | −$117.44M | −$97.00M | −$131.20M | −$98.54M |
| Assets | $1.26B | $1.16B | $1.27B | $1.14B |
| Liabilities | $329.65M | $322.78M | $339.93M | $131.09M |
| Equity | $926.39M | $835.18M | $926.10M | $1.01B |
Technicals
Massive · Nov 12, 2026- 50-day average19.86
- 200-day average21.24
- RSI (14 days)44.5
Short interest
Massive · Oct 30, 2026- Oct 30, 202614.69M shares · 9.9 days to cover
- Oct 15, 202615.48M shares · 8.1 days to cover
- Sep 30, 202615.46M shares · 7.6 days to cover
- Sep 15, 202617.14M shares · 12.0 days to cover
Related companies
MassiveNews coverage
No stories about Denali Therapeutics Inc. right now.